Biosimilars Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Peg-filgrastim, Monoclonal Antibodies, and Others), By Disease Indication (Cancer, Autoimmune Diseases {Arthritis, Psoriasis, and Others}, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030

ATTRIBUTE

DETAILS

Study Period

2017-2030

Base Year

2022

Estimated Year 

2023

Forecast Period

2023-2030

Historical Period

2017-2021

Growth Rate

CAGR of 17.3% from 2023 to 2030

Unit

Value (USD Billion)

Segmentation

By Drug Class

• Filgrastim & Peg-filgrastim
• Monoclonal Antibodies
• Others

By Disease Indication

• Cancer
• Autoimmune Diseases
• Arthritis
• Psoriasis
• Others
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Class, Disease Indication, Distribution Channel, and Country/Sub-Region)
• U.S. (By Drug Class)
• Canada (By Drug Class)
• Europe (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
• U.K. (By Drug Class)
• Germany (By Drug Class)
• France (By Drug Class)
• Italy (By Drug Class)
• Spain (By Drug Class)
• Scandinavia (By Drug Class)
• Rest of Europe (By Drug Class)
• Asia Pacific (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
• China (By Drug Class)
• India (By Drug Class)
• Japan (By Drug Class)
• Australia (By Drug Class)
• Southeast Asia (By Drug Class)
• Rest of Asia Pacific (By Drug Class)
• Latin America (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
• Brazil (By Drug Class)
• Mexico (By Drug Class)
• Rest of Latin America (By Drug Class)
• Middle East & Africa (By Drug Class, Disease Indication, Distribution Channel, and Country/ Sub-Region)
• GCC (By Drug Class)
• South Africa (By Drug Class)
• Rest of the Middle East & Africa (By Drug Class)